Dive into the future of biotech with Clora's CEO Rahul Chaturvedi as they explore entrepreneurship, hiring talent with an eye towards building a culture, and growing VC funded companies with Raymond Stevens, CEO of Structure Therapeutics, a trailblazer in structure-based drug discovery. Biotech2050 is a weekly podcast hosted by Rahul focusing on the future of Biotech. Don't miss this episode of Biotech2050! #Biotech #Innovation #Clora
Clora’s Post
More Relevant Posts
-
Xaira Therapeutics Debuts with $1B, Eyes AI Revolution in Medicine - Substantial Launch Capital: Xaira Therapeutics, headquartered in San Francisco, CA, has launched with over $1 billion in funding from notable investors including ARCH Venture Partners and Sequoia Capital. - Leadership and Experience: Led by Dr. Marc Tessier-Lavigne, a prominent figure with extensive leadership experience, Xaira aims to integrate AI into every phase of drug discovery and development. - AI-Driven Biotechnology Focus: Xaira is focused on using AI to accelerate drug discovery, promising significant advancements in biotechnology with a strong team and high-profile board members. Subscribe to our daily newsletter here for more AI news https://lnkd.in/dj-Vnmmu #Healthcare #Innovation #VentureCapital #Startups #Biotechnology #ArtificialIntelligence #Entrepreneurship #Research #Funding #Pharmaceuticals #AI
Xaira Therapeutics Debuts with $1B, Eyes AI Revolution in Medicine
http://eksentricity.ai
To view or add a comment, sign in
-
💊𝗕𝗹𝗼𝗴𝗴𝗲𝗿 #ConnectingInforming #DrugDiscoverytoDrugDelivery 💻𝗩𝗶𝗱𝗲𝗼 𝗖𝗼𝗻𝘁𝗲𝗻𝘁 𝗖𝗿𝗲𝗮𝘁𝗼𝗿 YouTube: RSK Life Science Media 📈𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁-LinkedIn/Marketing/Media/Events, Brand Champion
#News: Xaira Therapeutics, described as an integrated biotechnology company, launched Tuesday with $1 billion in an effort to transform #drugdiscovery and #drugdevelopment using #artificialintelligence. The San Francisco-based startup has brought together big names in AI research, drug development and venture capital to build and use an R&D platform. ARCH Venture Partners and Foresite Labs jointly incubated the #biotech and contributed funding. The funding from ARCH, which lists Alnylam Pharmaceuticals and Illumina among its successes, is the largest initial commitment in the almost 40-year history of the fund. Robert Nelsen, managing director and co-founder of ARCH, explained the thinking behind the big bet. “We have reached the point where AI finally allows us to see biology in new ways, and translate those discoveries to better treatments for disease,” Read more from BioSpace 👇🏼 https://lnkd.in/dktfbJGv
AI-Powered Xaira Launches with $1B, Ex-Genentech Execs Look to Transform R&D | BioSpace
biospace.com
To view or add a comment, sign in
-
#Austrian #biotech startup #HeartBeatbio raises € 4.5 million pre-series A round funding. Invest AG, aws Gründungsfonds II, and Tensor Ventures. The financing enables the completion of a ready-to-use, fully integrated, #automated, high-throughput Cardioid Drug #Discovery Platform for proprietary and #collaborative drug discovery programs in indications with a high medical need such as drug-induced and genetic #cardiomyopathies as well as #myocardial #infarction and fibrosis. HeartBeat.bio is building the #worldwide first high-throughput human organoid #cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure; faster, less #expensively and with a higher #probability of success in clinical trials. HeartBeat.bio AG Invest AG aws Gründungsfonds Tensor Ventures Michael Krebs Tomas Marsalek To share your startup story write us on - [email protected] #heartbeatbio #funding #eustartup
[Funding alert] Austrian biotech Startup HeartBeat.bio Raises € 4.5 million Pre-Series A Round Funding
https://startuprise.co.uk
To view or add a comment, sign in
-
Congratulations to Rubedo Life Sciences, a biopharmaceutical company with a focus on age-related diseases that secured $40 million in Series A funding yesterday. The round was led by investors Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, and others. “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan.” #RubedoLifeSciences #biotech #biotechfunding #clinicalresearch #clinicalresearchupdates
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital | BioSpace
biospace.com
To view or add a comment, sign in
-
#fundingalert 💼Company: Neurenati Therapeutics 💰Funding: $1.2Million ⚡Round: Seed 👥Investors: Genson Capital Neurenati Therapeutics was founded by Nicolas Pilon, Rodolphe Soret. The funding will be used by the company to expedite the development of NEU-001. A cutting-edge #biotechnology startup called Neurenati Therapeutics is creating a novel therapy for Hirschsprung’s illness. The company is dedicated to getting this treatment into clinical practice and has the backing of multiple #medical professionals, including #gastroenterologists and experts in clinical trials on rare disorders. Maxime Ranger Zhizi Zhao Benoit Dore Alexandre LeBeaut François Boutin, CPA Read more - https://lnkd.in/grySxF9a To share your startup story write us on - [email protected] #neurenatitherapeutics #biotechnology #meditech #news #healthtech #funding #startup
To view or add a comment, sign in
-
-
SVP @ SciPro | Life Sciences Staffing Expert | Leading a Team of True Recruitment Specialists Covering the Full Drug Development Life Cycle
The biotech financing landscape is showing signs of recovery, but it's a story of contrasts. Established companies with clinical-stage assets and experienced teams are thriving, raising substantial funds. However, early-stage biotechs and those without proof-of-concept data are struggling, facing tough financing conditions and lower valuations. While public markets remain challenging, venture capital is cautiously returning, with larger but fewer funding rounds. The gap between the "haves" and "have-nots" in biotech is widening. #biotech #pharma #funding #VC #PE #CGT #Oncology #lifesciences
Biotech financing: darkest before the dawn - Nature Biotechnology
nature.com
To view or add a comment, sign in
-
How many unicorns founded in the last 20 years have achieved both $1B in cash and revenue? And of these, how many do you think are pharma companies? Check out my latest Forbes article on Bruce Cozadd, Co-Founder, CEO, and Chairman of Jazz Pharmaceuticals, for insights into building a top biotech/pharma company with a strong focus on culture. There are some real gems in here for entrepreneurs and industry leaders alike. #biotech #pharma #entrepreneurship
How this CEO Built A Top 50 Pharma Company Focusing On Culture Day 1
forbes.com
To view or add a comment, sign in
-
Now teaming up to help biotech & pharma companies turn vision into reality. Deep Pharma Launch Experience / NED / Investor & nice Chap
Focus on your people and success will follow
How many unicorns founded in the last 20 years have achieved both $1B in cash and revenue? And of these, how many do you think are pharma companies? Check out my latest Forbes article on Bruce Cozadd, Co-Founder, CEO, and Chairman of Jazz Pharmaceuticals, for insights into building a top biotech/pharma company with a strong focus on culture. There are some real gems in here for entrepreneurs and industry leaders alike. #biotech #pharma #entrepreneurship
How this CEO Built A Top 50 Pharma Company Focusing On Culture Day 1
forbes.com
To view or add a comment, sign in
-
🔍 Would you like to find out who bagged the biggest private biotech investments in October 2023? 📊 Well, we have compiled a list for you of the most significant investments that took place last month, using data sourced directly from Crunchbase. 🚀 The companies Aiolos Bio, MapLight Therapeutics, Inc., and Agomab Therapeutics bagged the biggest biotech investments. And, players focused on biomaterials, the central nervous system, and musculoskeletal disorders attracted the most investor interest overall. 🌟 Meanwhile, other companies that bagged big investments included Rampart Bioscience, Atom Bioscience, AstronauTx, and Sirius Therapeutics, among others. 💡 So, to discover all of the companies that raised the largest private investment rounds in biotech in October, take a look at our latest article! https://lnkd.in/dSjgdegi #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding
The biggest private biotech investments in October 2023
https://www.labiotech.eu
To view or add a comment, sign in
-
Introducing Arin Ghasparian, CEO of grow member company Shape Biopharmaceuticals: Learn more about how he wants to transform immunotherapy in this interview with Venturelab
Shape Biopharmaceuticals Inc. shapes the future of immunotherapy. Get fascinated by the work of Venture Leader Arin Ghasparian who currently showcases his technology in Boston, with the Swiss National Biotech Team: https://lnkd.in/e76CFFRh For more information and updates on Shape Biopharmaceuticals and the Venture Leaders Biotech 2024, follow #VLeadersBiotech on social media and on https://lnkd.in/dsdBqy2E This year's Venture Leaders Biotech program is co-organized by Venturelab and Swissnex in Boston and New York and supported by Debiopharm, EPFL, ETH Zürich, Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association and VISCHER. #VLeadersBiotech #SwissStartups
Shape Biopharmaceuticals: The Venture Leader Biotech shaping the future of immunotherapy
venturelab.swiss
To view or add a comment, sign in